$19.54 +1.84 (10.40%)
Nanobiotix S.A. American Depositary Shares (NBTX)
Company News
NANOBIOTIX annonce de nouveaux résultats de Phase 1 qui continuent de confirmer le potentiel de JNJ-1900 (NBTXR3), avec un anti-PD-1, en tant que potentielle nouvelle option thérapeutique de première ou deuxième ligne ou plus dans le CETEC R/M naïf ou résistant aux anti-PD-1
NANOBIOTIX reported promising Phase 1 clinical trial results for JNJ-1900 (NBTXR3), a nanoparticle-based cancer treatment, showing favorable safety profile and potential efficacy in treating recurrent/metastatic head and neck squamous cell carcinoma patients, both naive and resistant to anti-PD-1 treatments.
CarMax Reports Downbeat Earnings, Joins Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling over 150 points on Thursday. Shares of CarMax, Inc. (NYSE: KMX) fell sharply in today’s pre-market trading after the company reported lower-than-expected fourth-quarter earnings. CarMax posted quarterly earnings of 32 cents per share, missing market estimates of 49 cent...